This past year has seen advances in the treatment of certain opportuni
stic protozoal infections in the immunocompromised patient, particular
ly microsporidiosis. Therapy for Pneumocystis carinii pneumonia is pre
sented, although this organism has been tentatively reclassified with
the fungi. Management of cryptosporidiosis remains difficult, at best,
and some diseases such as leishmaniasis still present specific challe
nges for the clinician. Updated information will include Acanthamoeba
and Cyclospora cayetanensis.